Stoke Therapeutics adds Alexander Cumbo to board after Kaye resignation
Edward Kaye, M.D. stepped down as a Class III director, and Stoke's board named Alexander (Bo) Cumbo to fill the seat effective September 23, 2026.
SEC filing
Latest
3 stories
Friday, September 25
Monday, August 3
Stoke Therapeutics files $200 million at-the-market stock offering
The August 3, 2026 prospectus supplement replaces a prior offering under which Stoke had already sold about 4.7 million shares for $146.4 million in net proceeds.
SEC filing
Stoke reports full EMPEROR enrollment, sets pre-NDA meeting and Q1 2027 filing start
Stoke Therapeutics said its Phase 3 EMPEROR trial in Dravet syndrome finished enrolling 162 patients, with a data readout expected in the third quarter of 2027 and a rolling NDA submission targeted to begin in early 2027
SEC filing